A degradation-resistant recombinant type I humanized collagen, its preparation method and application

By designing recombinant collagen single chains with specific fragment combinations of human type I collagen α1 chain, the degradation and immunogenicity problems of recombinant type I collagen have been solved, achieving the preparation of collagen with high stability and high purity, suitable for cosmetics, medical devices and pharmaceuticals.

CN123106882APending Publication Date: 2026-11-17ZHEJIANG CHONGSHAN BIOLOGICAL PROD CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611611985.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing recombinant type I collagen is prone to degradation during expression, purification, and storage, has insufficient stability, and poses an immunogenicity risk, making it difficult to meet the requirements for high stability applications.

Method used

The recombinant collagen single chain is designed by combining specific amino acid fragments of the human type I collagen α1 chain, and is prepared by prokaryotic or eukaryotic expression systems to ensure complete human sequence coverage and avoid non-natural linker peptides. High purity and high stability are achieved by expressing it with Pichia pastoris.

Benefits of technology

It achieves high purity (98%) and high stability (maintaining structural stability after 7 days of storage at 57-60℃), reduces immunogenicity, is suitable for industrial production, and has significant cell proliferation and adhesion promoting effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106882A_ABST
    Figure CN123106882A_ABST
Patent Text Reader

Abstract

This invention discloses an anti-degradation recombinant type I humanized collagen, its preparation method, and its applications, relating to the field of genetic engineering technology. The recombinant type I humanized collagen comprises recombinant collagen single chains; wherein the recombinant collagen single chain is formed by repeating collagen monomer fragments as shown in SEQ ID NO.2 2-10 times. The amino acid sequence of this invention is entirely derived from the cutting and splicing of the natural sequence of human type I collagen, without introducing any non-human exogenous amino acid residues or non-natural linker peptides, achieving 100% human sequence coverage. Its sequence is theoretically completely identical to the corresponding region of natural human collagen, thus exhibiting extremely low immunogenicity, completely avoiding the risk of viruses carried by animal-derived collagen and allergic reactions caused by foreign proteins, demonstrating excellent biocompatibility and high safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of genetic engineering technology, specifically to an anti-degradation recombinant type I humanized collagen, its preparation method, and its application. Background Technology

[0002] Collagen is the most abundant structural protein in mammals and a major component of the extracellular matrix, playing a crucial role in maintaining tissue tension, promoting cell adhesion, proliferation, and differentiation. Type I collagen is one of the most widely used collagen types in tissue engineering, medical devices, cosmetics, and pharmaceuticals. Currently, the preparation of type I collagen mainly relies on animal tissue extraction methods, such as acid hydrolysis and enzymatic hydrolysis, with common sources including bovine Achilles tendon, pig skin, and rat tail. However, animal-derived extraction has several inherent limitations: firstly, there is a risk of pathogen transmission, such as mad cow disease and foot-and-mouth disease virus, and the extraction process may leave behind immunogenic components such as telopeptides, causing immune rejection reactions; secondly, individual animal differences lead to batch-to-batch quality instability, and the extraction process cannot completely remove impurities and other types of collagen.

[0003] To address these issues, recombinant collagen technology has become a research hotspot in recent years. By transferring the gene sequence encoding type I collagen into engineered hosts such as *E. coli*, *Pichia pastoris*, and mammalian cells using genetic engineering techniques, controllable, animal-free, and highly homogeneous collagen production can be achieved. However, type I collagen is a heterotrimer assembled from two different types of α-chains, and its recombinant synthesis presents significant technical challenges: on the one hand, achieving co-expression and stoichiometric balance of the two α-chains in host cells is necessary; on the other hand, prokaryotic and lower eukaryotic expression systems often lack collagen-specific post-translational modifications, such as the action of proline hydroxylase, affecting the triple helix structure and functional activity; furthermore, achieving correct chain recognition and assembly in vitro or intracellularly, and avoiding the generation of byproducts such as homotrimers, remain key bottlenecks that urgently need to be overcome in the field.

[0004] Chinese patent CN105061589A discloses a technical solution for producing recombinant human type I collagen using an immobilized fermentation method. This existing technology uses the human type I collagen sequence as a basis for recombinant expression, which can, to some extent, avoid the pathogen risks and batch instability issues associated with animal-derived collagen. However, human type I collagen has a heterotrimeric structure, and the recombinant expression process requires the co-expression and correct assembly of different α-chains. Chain recognition and stoichiometric equilibrium in the host cell are difficult to control precisely, easily leading to byproducts such as homotrimers. Furthermore, prokaryotic and lower eukaryotic expression systems have limited post-translational modification capabilities for collagen, affecting the correct formation of the triple helix structure. In addition, the resulting recombinant human type I collagen still possesses sensitive sites that are easily deamidated, hydrolyzed, or oxidized, making it prone to degradation during expression, purification, storage, and use, resulting in insufficient stability and making it difficult to meet the requirements of applications with high stability requirements.

[0005] To address the stability issue, Chinese patent CN116082493A obtained recombinant collagen with improved stability by mutating the amino acid sequence, thus improving the product's storage stability to some extent. However, this prior art alters the natural sequence of human collagen through amino acid mutation. The mutated sequence carries the risk of being recognized as a foreign substance by the body, potentially leading to increased immunogenicity and safety concerns. Furthermore, the impact of amino acid mutations on the natural conformation, biological activity, and biocompatibility of collagen is difficult to predict and control, making it challenging to balance stability and safety.

[0006] Therefore, how to provide a recombinant type I humanized collagen that has good anti-degradation stability, low immunogenicity, and natural biological activity remains a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0007] Therefore, the present invention provides an anti-degradation recombinant type I humanized collagen, its preparation method and application, to solve the problems in the prior art.

[0008] To achieve the above objectives, the present invention provides the following technical solution: According to a first aspect of the present invention, a recombinant type I humanized collagen with anti-degradation properties is provided, wherein the recombinant type I humanized collagen comprises a recombinant collagen single chain; wherein the recombinant collagen single chain is composed of collagen monomer fragments as shown in SEQ ID NO.2 repeated 2-10 times. As an example, optionally, the collagen single chain contains 4-8 collagen monomer fragments; preferably, the collagen single chain contains 6-7 collagen monomer fragments; most preferably, the collagen single chain contains 7 collagen monomer fragments.

[0009] COL1 recombinant collagen monomer fragment amino acid sequence SEQ ID NO.2: GPPGPKGNSGEPGAPGSKGDTGAKGEPGPPPGPAGPRGANGAPGNDGAKGDA.

[0010] Furthermore, the recombinant collagen single chain is obtained by cutting and splicing human type I collagen α1 chain; wherein the amino acid sequence of the human type I collagen is shown in SEQ ID NO.1.

[0011] COL1A1 amino acid sequence SEQ ID NO.1:

[0012] Furthermore, the collagen monomer fragment is obtained by sequentially combining amino acids at positions 425-451 and 689-712 of human type I collagen, wherein the amino acid sequence of human type I collagen is shown in SEQ ID NO.1.

[0013] Furthermore, the amino acid sequence of the recombinant collagen single chain is shown in SEQ ID NO.3.

[0014] COL1 recombinant collagen single-chain amino acid sequence SEQ ID NO.3: GPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGE PGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDAGPPGPKGNSGEPGAPGSKGDTGAKGEPGPPGPAGPRGANGAPGNDGAKGDA.

[0015] Furthermore, the nucleotide sequence encoding the recombinant collagen single chain is shown in SEQ ID NO.4.

[0016] COL1 nucleotide sequence SEQ ID NO.4:

[0017] A method for preparing recombinant collagen single chains according to a second aspect of the present invention includes the following steps: Step 1: Design collagen sequences The amino acids at positions 425-451 and 689-712 of human type I collagen are sequentially combined to obtain collagen monomer fragments. The collagen monomer fragments are repeated 2-10 times to obtain recombinant collagen single chains. Step 2, constructing the carrier Based on the recombinant collagen single-chain, the corresponding nucleotide sequence was synthesized to construct a recombinant plasmid; Step 3: Transformation and Cultivation The recombinant plasmid was transferred into host cells, engineered strains were screened, and fermentation culture was performed to induce the expression of the target protein. Step 4: Harvesting and Purification The fermentation broth was collected, the expressed protein product was harvested, and purified to obtain the target collagen.

[0018] Furthermore, in step two, the plasmid is selected for prokaryotic expression, specifically the pET series vector, pGEX series vector, pBAD series vector or pUC series vector; or the plasmid is selected for eukaryotic expression, specifically the pcDNA series vector, pCMV series vector, pIRES series vector, pEGFP series vector, pYES series vector or pPIC series vector. Optionally, plasmids include pcDNA3.1, pCMV-Tag, pCMV-Sport, pIRES2-EGFP, pEGFP-C1, pYES2, pPICZ, and pPIC3.5.

[0019] Furthermore, in step three, the host cell is a prokaryotic cell, a yeast cell, or a mammalian cell; for example, the prokaryotic cell is Escherichia coli or Bacillus subtilis; the yeast cell is Pichia pastoris or Saccharomyces cerevisiae; and the mammalian cell is HEK293 cell or CHO cell.

[0020] The anti-degradation recombinant type I humanized collagen prepared by the method described above, according to a third aspect of the present invention, is used in the preparation of collagen-containing products.

[0021] Furthermore, the collagen product is a cosmetic, medical device, or drug.

[0022] Optionally, the drug includes wound repair materials, cartilage repair materials, and drug delivery carriers; Optionally, the medical device includes tissue engineering materials, surgical aids, and dental prosthetic materials; Optionally, the cosmetics include skin care products, hair care products, and anti-aging products.

[0023] In one embodiment, the medicine includes, but is not limited to, wound healing materials, such as collagen sponge (to promote wound healing), collagen hemostatic dressing (for rapid hemostasis), and collagen membrane (for postoperative repair). Cartilage repair materials, such as collagen injections (for repairing articular cartilage defects) and collagen-based cartilage grafts; Drug delivery carriers, such as collagen microspheres (encapsulating active ingredients for sustained drug release) and collagen gel injections (for local delivery of anti-inflammatory or anti-tumor drugs).

[0024] In one embodiment, the medical device includes, but is not limited to, tissue engineering materials, such as collagen scaffolds (for cell culture and tissue regeneration), collagen-based composite materials (for bone or soft tissue repair), and collagen filler materials (for filling tissue or cavities). Surgical aids include, but are not limited to, collagen sutures (biodegradable sutures) and collagen hemostatic sponges (for intraoperative hemostasis). Oral restoration materials include, but are not limited to, collagen membranes (alveolar bone filling) and collagen periodontal regeneration materials.

[0025] In one embodiment, cosmetics include skincare products, such as collagen masks (moisturizing, repairing, and anti-aging), collagen serums (improving skin elasticity), and collagen lotions (hydrating and locking in moisture). Hair care products, such as collagen shampoo (to repair damaged hair) and collagen conditioner (to replenish nutrients and make hair smooth). Anti-aging products, such as collagen anti-wrinkle cream (to improve skin firmness) and collagen freeze-dried powder (to promote skin regeneration and repair fine lines).

[0026] The present invention has the following advantages: This invention selects amino acids at positions 425-451 and 689-712 of the α1 chain of human type I collagen to obtain a collagen monomer fragment. This design eliminates a large number of non-functional or low-activity regions, enriching the core active epitopes of type I collagen in a compact structure. The resulting recombinant collagen significantly promotes cell proliferation, cell adhesion, and cell migration, exhibiting excellent biological activity.

[0027] The amino acid sequence of this invention is entirely derived from the cutting and splicing of the natural sequence of human type I collagen, without introducing any non-human exogenous amino acid residues or non-natural linker peptides, and has 100% human sequence coverage. Its sequence is theoretically completely identical to the corresponding region of natural human collagen, therefore it has extremely low immunogenicity, completely avoiding the risk of viruses carried by animal-derived collagen and allergic reactions caused by foreign proteins, exhibiting excellent biocompatibility and high safety.

[0028] The recombinant type I humanized collagen prepared by this invention exhibits excellent anti-degradation properties. During expression in Pichia pastoris, the target protein band was single, with no obvious degradation bands. High expression levels were observed in 5L-scale fermentation, and subsequent purification was easy. The purification recovery rate reached 95%, and the purity reached 98%, making it suitable for industrial-scale production.

[0029] The recombinant type I humanized collagen prepared by this invention exhibits excellent stability. It maintains good structural and purity stability after being stored at 57-60℃ for 7 days; it also remains stable at room temperature under different pH conditions, demonstrating excellent clinical pH suitability. Attached Figure Description

[0030] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are merely exemplary, and those skilled in the art can derive other embodiments based on the provided drawings without creative effort.

[0031] The structures, proportions, sizes, etc. illustrated in this specification are only for the purpose of assisting those skilled in the art in understanding and reading the content disclosed herein, and are not intended to limit the conditions under which the present invention can be implemented. Therefore, they have no substantial technical significance. Any modifications to the structure, changes in the proportions, or adjustments to the size, without affecting the effects and objectives that the present invention can produce, should still fall within the scope of the technical content disclosed in the present invention.

[0032] Figure 1 This is a plasmid map of recombinant type I humanized collagen expression provided in Example 1 of the present invention.

[0033] Figure 2 This is the SDS-PAGE detection result of the supernatant of recombinant collagen expression from Pichia pastoris genetically engineered bacteria in Example 1 of this invention. Where M: Marker.

[0034] Figure 3The results are from the SDS-PAGE analysis of the supernatant from a 5L-scale fermentation process provided in Example 1 of this invention. Wherein, M is the marker; 1 and 2 are dilutions of the fermentation supernatant; and 3 is the fermentation supernatant itself.

[0035] Figure 4 This is the SDS-PAGE electrophoresis pattern of COL1-3 protein purification provided in Example 1 of the present invention; wherein, M is Marker; 2 is flow-through buffer; and 1 is elution buffer.

[0036] Figure 5 This refers to the stability of the COL1-3 protein provided in Experiment 1 of this invention when stored at 60°C; where M is the protein marker.

[0037] Figure 6 This refers to the pH stability of the COL1-3 protein provided in Experimental Example 1 of this invention.

[0038] Figure 7 The results of experiments on cell proliferation, cell adhesion, and cell migration of C17A1T01 protein provided in Experiment Example 1 of this invention are as follows.

[0039] Figure 8 This is a diagram showing the evaluation results of diabetic wound healing provided in Experimental Example 2 of the present invention.

[0040] Figure 9 The circular dichroism (CD) chromatogram of COL1 protein provided in Experimental Example 4 of this invention. Detailed Implementation

[0041] The following specific embodiments illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0042] Unless otherwise specified in the embodiments of this invention, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available products; different manufacturers and models of raw materials do not affect the implementation of the technical solution or the achievement of the technical effect of this invention.

[0043] Yeast extract: Oxoid, LP0021B; Peptone: Oxoid, LP0042B; YNB: Shanghai Yuanye Biotechnology Co., Ltd., S24483; Glycerin: Ruikangda, GY20250113; Biotin: Aladdin, D2317484; Potassium phosphate buffer: Beijing Solarbio Science & Technology Co., Ltd., P1030.

[0044] Seed culture medium YPD (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose); BMGY medium (1% yeast extract + 2% peptone + 1.34% YNB + 1% glycerol + 0.0004% biotin + 100 mM potassium phosphate buffer, pH 6.0); BMMY medium (1% yeast extract + 2% peptone + 1.34% YNB + 0.0004% biotin + 100 mM potassium phosphate buffer, pH 6.0); Fermentation medium (46 g / L glycerol, 2.02 g / L magnesium sulfate heptahydrate, 0.46 g / L calcium sulfate dihydrate, 9.1 g / L potassium sulfate, 11.34 mL / L phosphate, 2.06 g / L potassium hydroxide, 4 mL / L PTM1 trace element); Fed medium (50% w / v glycerol, 12 mL / L). PTM1 trace elements); induction medium (100% methanol, with 12 mL of PTM1 trace elements added per liter); PTM1: sterilized by filtration through a 0.22 μm filter membrane and stored at 4℃. After the fermentation medium is sterilized at high temperature, PTM1 is added after the temperature drops to room temperature, and the pH is adjusted to 5.0 with ammonia.

[0045] pPICZα empty vector was purchased from Thermo Fisher Scientific; SacI, EcoRI, and NotI were all purchased from Takara.

[0046] Example 1 Design and expression of synthetic human type I collagen COL1-7 1. Design collagen sequences Based on the sequence of human type I collagen (https: / / www.uniprot.org / uniprot / P02461; COL1A1, amino acid sequence as shown in SEQ ID NO.1), recombinant collagen was designed. Amino acids 425-451 and 689-712 were sequentially combined to obtain recombinant collagen monomer fragment 3, amino acid sequence as shown in SEQ ID NO.2. SEQ ID NO.2 was repeated 7 times to obtain a single chain of recombinant collagen, named COL1-7, amino acid sequence as shown in SEQ ID NO.3.

[0047] 2. Construction of recombinant plasmids and recombinant bacteria The amino acid sequence SEQ ID NO.2 obtained in step 1 was used to complete the corresponding nucleotide sequence (SEQ ID NO.4) at Nanjing Genscript Biotech Co., Ltd., and then inserted into the α-factor reading frame of the pPICZα empty vector (purchased from Thermo Fisher Scientific). The resulting recombinant plasmid was named pPICZα-COL1-7 (COL1-3pPICZalphaA, amino acid sequence SEQ ID NO.2, nucleotide sequence SEQ ID NO.4). A schematic diagram of the plasmid is shown below. Figure 1 As shown.

[0048] The above recombinant plasmid (2-3 μg) was digested with SacⅠ (purchased from Thermo Fisher) at 37℃ for 2 h, linearized, recovered, and electroporated into Pichia pastoris X33 competent cells; the electroporated bacterial culture was plated on YPD / Zeocin plates and incubated upside down at 30℃ for 2-5 days. Single colonies were selected to verify the Pichia pastoris genetic engineering, which was named P. pastoris-COL1-7.

[0049] 3. Induced expression and identification of recombinant collagen The Pichia pastoris genetically engineered strains obtained in step 2 were inoculated into 50 mL centrifuge tubes containing 5 mL of BMGY medium and cultured at 28-30℃ and 220 rpm until OD reached. 600 The result was 10 (48 h). The cells were centrifuged at 3500 g for 5 min at room temperature, collected, and resuspended in BMMY medium to adjust the OD value. 600 The culture medium was 10, and the culture was placed on a shaker at 28℃ and 220rpm for 3 days. Anhydrous methanol was added to the culture medium every 24 hours until the final concentration was 1.0%. Bacterial culture samples were collected at 48h and 72h after methanol induction. The sample volume was 1mL and placed in a 1.5mL EP tube. The tube was centrifuged at 12000g for 5min at 4℃ and the expression supernatant was collected. The samples to be tested were stored at -80℃ for later use.

[0050] The results of SDS-PAGE analysis of the supernatant are as follows: Figure 2 As shown, the results indicate that the sequence can be secreted into the culture medium supernatant, and the band is single.

[0051] 4. Fermentation expression and purification of COL1-7 protein 1. Glycerol batch culture: Accumulate biomass to OD 600 Upon reaching the critical value of 30, glycerol-fed culture was initiated, with 50% glycerol (containing 12 mL / L PTM1) added at a rate of 4-6 mL / L / h, continuing the reaction until the OD value was reached. 600=100±20; During the methanol induction phase, the methanol flow rate was gradually increased (each liter of methanol contained 12 mL of PTM1). The flow rate was low (2 mL / L / h) for 0-12 hours to avoid methanol toxicity. For 12-24 hours, the flow rate was increased to 4 mL / L / h, and DO fluctuations were monitored. For 24-96 hours, the flow rate was high (6 mL / L / h) to maintain DO at 10%-20%. Samples were taken every 12 hours to detect expression levels and purity. Induction was continued for 72-96 hours to maximize protein secretion.

[0052] 2. Collection and purification of expression products The fermentation broth was centrifuged at 3000 g at room temperature, and the supernatant was collected. The supernatant was then diluted with purified water until the final solution conductivity was <5 mS / cm.

[0053] Cation exchange resin (Borglon, Diamond SP Mustang, catalog number AI0192) was used for separation and purification by chromatography. (1) Equilibration: 10mM PBS, pH 7.0 ± 0.1; wash with 3 column volumes and drain waste liquid; (2) Sample loading: After centrifugation, collect the supernatant of the fermentation broth and add it to the chromatography column, where it flows through the column resin by gravity; (3) Washing: 10 mM PBS, pH 7.0 ± 0.1; wash with 5 column volumes; (4) Elution: 10mM PBS, 0.5M NaCl, pH 7.0 ± 0.1; use 3 column volumes for elution; (5) CIP cleaning: 500mM NaOH; flush with 5 column volumes.

[0054] 3. Protein identification and analysis The eluent containing synthetic human type I collagen COL1-7 was collected and subjected to SDS-PAGE. The results are as follows: Figure 4 As shown: The purified recombinant type I humanized collagen was a monomer with an apparent molecular weight of approximately 60 kDa. The purification recovery rate reached 95%, and the purity reached 98%. Ultrafiltration concentration yielded the synthetic type I humanized collagen COL1-7 stock solution.

[0055] Example 2 To screen for the optimal number of replicates, recombinant collagen single chains with replicates of 1, 2, 4, 6, 7, 8, and 10 were constructed under the same conditions as in Example 1, and named COL1-1, COL1-2, COL1-4, COL1-6, COL1-7 (i.e., COL1-7 in Example 1), COL1-8, and COL1-10, respectively. They were prepared using the same expression and purification conditions (as in Example 1), and their performance was tested according to the methods in Examples 1-4. The results are shown in Table 1.

[0056] Table 1 Performance comparison at different number of repetitions

[0057] Table 1 shows that the best overall performance was achieved with 7 repetitions, with the main band accounting for 89% of the total. It remained stable after heating at 60℃ for 7 days, forming a typical triple helix structure, and both cell adhesion and proliferation rates reached their peak. Repetitions of 6 and 8 showed performance similar to 7 repetitions, exhibiting good stability and biological activity. With fewer repetitions, although expression stability was highest, biological activity was significantly lower. Because the monomeric fragment contained only one set of functional domains and had a small molecular weight, it could not form a stable triple helix structure, resulting in cell adhesion and proliferation rates far lower than with 7 repetitions. With too many repetitions, the proportion of the main band continuously decreased with increasing repetition count, and the stability after heating at 60℃ for 7 days gradually deteriorated from "basically stable" to "slightly degraded." This is because excessively high repetition counts amplified the protease recognition sites and unstable local secondary structures hidden in the sequence, leading to non-specific degradation of the target protein during fermentation. Simultaneously, biological activity also decreased with increasing repetition count.

[0058] Example 3 To screen for the optimal fragment combination, under the same conditions as in Example 1 (all repeated 7 times), recombinant collagen single chains with the following different fragment combinations were constructed: (1) COL1-7 (this invention): bits 425-451 + bits 689-712 (i.e., the SEQ ID NO.2 fragment), repeated 7 times; (2) COL1-Nat (natural continuous sequence): The natural continuous amino acid sequence of human type I collagen from position 425 to 712 (SEQ ID NO.5) was selected and repeated 7 times; COL1-Nat amino acid sequence SEQ ID NO.5: GPPGPKGNSGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGLPGPPGERGGPGSRGFPGADGVAPGKPAGERGSGPGAPGKGPSGEAGRPGEAGLPGAGKLGTGSPGSPGDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGVPGPPGAVPGAGKDGEAGAQQPPGAPAGERGEQPGASPGFQGLPGPAGPPGEAGKPGEQGVPGDLGAPGPGARGERGFPGERGVQGPPGAPGRGANGAPGNDGAKGDAGAPGAPGSQGAPGLQGMGPGERGAAGLPGPKGDRGDAGPKGADGSPGKDGVRLGTPGIPGPGAPAGPDKGESGSPGAPGTPGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGEPGDAAGKGDAGPPGAPGAPGPPGPNGVGAPGAKGARGSAAGPPGATGFPGAAGRVGPPGPSGNAGPPGPPGAPGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGPAGAPGTPGPGIAGQRGVVGLPGQRGERGFPGLPGPSGEPGKGQPSGASGERGPPGPMGPPGLAGPPGESGREGAPGAEGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGAPGPVGPVGARGPAGPQGPRGDKGETEQGDRGIKGHRGFSGLQGPGPPGPSPGEQGPSGASGPAGRGPPGSAGAPGKDLGNLPGPGIPGPGPRGRGTGDAGPVGPPGPPGPPGPPGSPASGFDFSFLPQPPQEKAHDGGRYYRADDANVVVRDRDLEVDTTLKSLSQIEINIRSPEGSRKNPARTCRDLKMCH.

[0059] (3) COL1-Rev (reverse splicing): positions 689-712 + positions 425-451 (the splicing order is reversed), repeated 7 times; (4) COL1-A: only the amino acid sequence at positions 425-451 (SEQ ID NO.6), repeated 7 times; COL1-A amino acid SEQ ID NO.6: GPPGPKGNSGEPGAPGSKGDTGAKGEP.

[0060] (5) COL1-B: only amino acids 689-712 (SEQ ID NO.7), repeated 7 times; COL1-B amino acid SEQ ID NO.7: GPPGPAGPRGANGAPGNDGAKGDA.

[0061] The same expression and purification conditions were used for preparation (same as in Example 1), and the performance was tested according to the methods of Experiments 1-4. The results are shown in Table 2.

[0062] Table 2 Performance Comparison of Different Fragment Combinations

[0063] Table 2 shows that while COL1-A and COL1-B, containing only single functional fragments, exhibit extremely high expression stability due to their short sequences, their cell adhesion and proliferation rates are significantly lower than those of COL1-7 in this invention due to the lack of a complete functional domain combination of type I collagen. This indicates that retaining only a single functional fragment cannot form a complete biological functional conformation, and a single fragment cannot replace the synergistic effect of multiple fragments. Although COL1-Nat retains the complete native sequence, the main band accounts for only 55%, and significant degradation occurs after heating at 60°C. This is because the native continuous sequence contains multiple protease recognition sites, and these sites are further amplified after repetition, leading to a large amount of non-specific degradation of the target protein during fermentation, making it difficult to achieve industrial production. COL1-Rev has a main band accounting for 76%, and slight degradation occurs after heating at 60°C. Its stability and activity are both lower than those of COL1-7 in this invention, indicating that the fragment splicing order has a significant impact on the protein's folding efficiency and exposure to protease attack sites. Therefore, the specific fragment combination and splicing order selected in this invention are key to obtaining high resistance to degradation and high bioactivity.

[0064] Example 4 Collagen hemostatic dressing was prepared using the synthetic type I humanized collagen COL1-7 stock solution obtained in Example 1: The synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1 was lyophilized to obtain COL1-7 lyophilized sponge. The hemostatic dressing comprises: 1.0%-2.0% (w / v) COL1-7 lyophilized sponge, 0.5%-1.0% (w / v) chitosan, 0.5%-2.0% (v / v) glycerol or sorbitol, 0.01%-0.1% (w / v) crosslinking agent (genipin / EDC), and water for injection to 100%.

[0065] Preparation method: The COL1-7 lyophilized sponge prepared in Example 1 was dissolved in water for injection to prepare a 2.5% (w / v) collagen solution. The solution was then magnetically stirred or stirred at low speed (4°C) to ensure complete dissolution and to avoid generating bubbles.

[0066] Weigh out the chitosan, dissolve it in 1% acetic acid solution to prepare a 3.0% chitosan solution, and filter to remove insoluble matter.

[0067] Mix collagen solution and chitosan solution at a volume ratio of 8:2 and stir slowly until homogeneous; add glycerol or sorbitol to a final concentration of 0.5% and stir until homogeneous; add genipin (final concentration 0.01%) and stir for 30 min to allow for full reaction, and the product is obtained.

[0068] Example 5 A collagen compound gel dressing was prepared using the synthetic type I humanized collagen COL1-7 stock solution obtained in Example 1: The synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1 was freeze-dried to obtain COL1-7 freeze-dried sponge. The gel dressing is divided into two parts, A and B. Part A is sterile freeze-dried, and the COL1-7 freeze-dried sponge contains 4 mg. Part B, by mass percentage, consists of: sodium hyaluronate 0.25%, carbomer 1%, propylene glycol 2.5%, glycerin 2%, methylparaben 0.05%, propylparaben 0.05%, and the remainder is purified water. Parts A and B are mixed thoroughly before use.

[0069] The preparation method is as follows: (1) Accurately weigh carbomer, sodium hyaluronate, glycerin, propylene glycol, methylparaben and propylparaben, stir for 1 h, add purified water and dissolve completely.

[0070] (2) Accurately weigh the COL1-7 freeze-dried sponge.

[0071] (3) Filling under aseptic conditions, sealing and packaging, and irradiation sterilization result in a type I recombinant collagen compound gel dressing product.

[0072] Instructions for use: Bottles A and B can be aseptically and quickly mixed before use.

[0073] Example 6 Collagen liquid dressing was prepared using the synthetic type I humanized collagen COL1-7 stock solution obtained in Example 1: The synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1 was freeze-dried to obtain COL1-7 freeze-dried sponge. The liquid dressing comprises: 5 mg / mL COL1-7 freeze-dried sponge, and the remaining components by mass percentage include: 0.05% sodium hyaluronate, 10% glycerol, 2% carbomer, and the balance being purified water.

[0074] The preparation method is as follows: (1) Accurately weigh carbomer, sodium hyaluronate and glycerin, stir for 1 h to dissolve completely.

[0075] (2) Accurately weigh COL1-7 lyophilized sponge, add purified water, and dissolve it completely.

[0076] (3) After mixing, fill under aseptic conditions, seal and package, and sterilize by irradiation to obtain the Type I recombinant collagen liquid dressing product.

[0077] How to use: After cleansing, apply evenly to the face and gently massage or pat until fully absorbed.

[0078] Comparative Example 1 Collagen hemostatic dressings were prepared using synthetic type I humanized collagen obtained from COL1-Nat (same as Example 4).

[0079] Comparative Example 2 Collagen compound gel dressings were prepared using synthetic type I humanized collagen obtained from COL1-Nat (same as Example 5).

[0080] Comparative Example 3 Collagen hemostatic dressings were prepared using synthetic type I humanized collagen obtained from COL1-Rev (same as Example 4).

[0081] Comparative Example 4 Collagen compound gel dressings were prepared using synthetic type I humanized collagen obtained from COL1-Rev (same as Example 5).

[0082] Comparative Example 5 Collagen hemostatic dressings were prepared using commercially available animal-derived type I collagen (extracted from bovine Achilles tendon) (same as Example 4).

[0083] Experimental Example 1 The properties of the synthetic type I humanized collagen COL1-7 stock solution obtained in Example 1 were tested: 1. Thermal stability The synthetic type I humanized collagen COL1-7 stock solution was prepared into a 10 mg / mL solution with ultrapure water, filtered through a 0.22 μm filter membrane, and then aliquoted into sterile centrifuge tubes. The tubes were heated at 60℃ for 0, 3, 5, and 7 days, and samples were taken for SDS-PAGE analysis.

[0084] The results are as follows Figure 5 As shown, the treated synthetic type I humanized collagen COL1-7 still maintains structural and purity stability, with no significant difference from 0 days; the protein structure was not destroyed at 60℃, and no serious degradation or diffusion occurred, proving that the synthetic type I humanized collagen COL1-7 has extremely high thermal stability.

[0085] 2. Acid and alkali tolerance stability test The stability of synthesized type I humanized collagen COL1-7 was tested under different pH conditions, and the results are as follows: Figure 6 As shown, the results indicate that the synthesized type I humanized collagen COL1-7 has good pH suitability, maintains strong stability at pH 6-8, and has good clinical pH suitability.

[0086] 3. Cell proliferation experiment Synthetic type I humanized collagen COL1-7 solution and BSA solution of the same concentration were prepared as experimental groups. PBS solution was added to the control group. Then, 100 μL of the solution was added to each well of a 96-well plate. Each sample was coated to prepare 3 wells. The plates were incubated in a 5% CO2 incubator at 37°C for 2 h. The excess coating solution was removed and the 96-well plates were refrigerated at 2-8°C overnight.

[0087] After digestion and cell counting, L929 cells were diluted with growth medium and seeded into 96-well plates at a density of 2000 cells / well (100 μL per well). The seeding time was recorded as 0 h. The cells were incubated at 37°C for 11 h in a 5% CO2 incubator. After incubation, 10 μL of CCK-8 solution was added to each well, and the cells were incubated again at 37°C for 1 h. The absorbance was then measured at 450 nm.

[0088] 4. Cell adhesion experiment Coating: Prepare synthetic type I humanized collagen COL1-7 solution and BSA solution of the same concentration as the experimental group. Add PBS solution to the control group. Add 100 μL of solution to each well of a 96-well plate. Coat 3 wells for each sample. Incubate at 37°C for 2 h in a 5% CO2 incubator.

[0089] Washing: Remove excess coating solution from the wells and wash twice with PBS solution.

[0090] Cell counting: Cells were resuspended in culture medium and counted. The cell count was diluted to a final concentration of 2 × 10⁻⁶. 5 per mL.

[0091] Assay: The cell suspension was aspirated and added to each well of a 96-well plate, 100 μL per well. After incubation at 37°C for 4 h in a 5% CO2 incubator, the culture medium was discarded. The cells were gently washed three times with PBS to remove any unadhered cells. Fresh culture medium was then added and cultured for 2 h. After incubation, 10 μL of CCK-8 solution was added to each well, and the plate was incubated for another 1 h. The absorbance was then measured at 450 nm.

[0092] 5. Cell migration experiment Coating: Prepare synthetic type I humanized collagen COL1-7 solution and BSA solution of the same concentration as the experimental group. Add PBS solution to the control group. Add 1.5 mL of solution to each well of a marked 6-well plate. Coat two wells for each sample. Incubate at 37°C for 2 h in a 5% CO2 incubator.

[0093] Washing: Remove excess coating solution from the wells and wash twice with PBS solution.

[0094] Cell counting: Cells were resuspended in culture medium and counted. The cell count was diluted to a final concentration of 3 × 10⁻⁶. 5 per mL.

[0095] Detection: Aspirate the above cell suspension and add 1 mL to each well of a 6-well plate. Incubate at 37°C for 20-24 h in a 5% CO2 incubator until 95%-100% confluence is achieved. Using a 1 mL pipette tip, gently push downwards along the horizontal marking line to create a scratch (approximately 1.0-1.5 mm wide). Gently wash twice with PBS to remove the scratched cells, then add 2 mL of fresh culture medium and incubate at 37°C in a 5% CO2 incubator. Observe the healing of the cell scratches under a microscope at 0 h and 16 h. Using the intersection of the horizontal and vertical scratches as the focal point, photograph the cells under a 40x microscope to obtain cell images for analysis.

[0096] Experimental results are as follows Figure 7 As shown, the results indicate that the synthesized type I humanized collagen COL1-7 has a significant promoting effect on cell proliferation, cell adhesion, and cell migration.

[0097] 6. Safety The testing should be conducted according to GB / T16886.5-2017, and the steps are as follows: The potential cytotoxicity of synthetic type I humanized collagen COL1-7 was tested using in vitro cultured mammalian L-929 cells. Synthetic type I humanized collagen COL1-7 (1 mg / mL, 2 mg / mL, 4 mg / mL) and control samples were placed in MEM medium containing 10% fetal bovine serum and incubated at 37°C for 24 hours. After extraction, 96-well plates (103) cultured for 24 hours were... 4 Remove the culture medium from each cell (cells / well), replace it with the appropriate extraction solution, and incubate in a cell culture incubator (37℃, 5% CO2, >90% humidity) for 24 hours.

[0098] After culture, cell morphology and cell lysis were observed under a microscope, and the cytotoxicity value of the test sample was determined using the CCK8 assay. The results showed that the blank control group and cells maintained normal morphology throughout the experiment, showing no cytotoxic reaction. After incubation at a concentration of 4 mg / mL for 24 hours, cell morphology remained largely intact, and cell viability approached 100%. This indicates that the synthetic type I humanized collagen COL1-7 had no cytotoxic effect under the CCK8 cytotoxicity assay conditions.

[0099] Experiment Example 2 An evaluation experiment was conducted on the healing of diabetic wounds using the products of Example 5 and Comparative Examples 2, 4, and 5: One hundred healthy SPF-grade SD rats, weighing between 230 and 250 g, were used. They were acclimatized for one week before the experiment, housed at a temperature of 20±3℃ and a relative humidity of 55±10%, with free access to food and water. Before modeling, each rat was fasted for 12 hours and injected with 1% STZ solution (prepared with citrate buffer) at a dose of 50 mg / kg. Thirty minutes after injection, food and water intake were no longer restricted. Blood glucose was measured from the tail vein 72 hours after injection. A blood glucose level ≥16.7 mM indicated successful modeling; rats that did not successfully model were excluded from the experiment. Rats with successful modeling were divided into 5 groups of 15 each.

[0100] A 2 cm diameter circle was cut on the back of a rat to obtain a skin lesion. The collagen compound gel dressings obtained in Example 5 and Comparative Examples 2, 4, and 5 were applied to the skin lesion twice daily for four weeks. The control group was treated with a phosphate buffer solution at pH 7.0. The diameter of the skin lesion was measured to confirm the wound healing effect.

[0101] The results are as follows Figure 8 As shown, by Figure 8It can be seen that the collagen compound gel dressing prepared in Example 5 of this invention has a good effect on promoting wound healing, and the wound healing rate reaches 99% after 28 days. Compared with the control group, the gels of Comparative Examples 2, 4, and 5 are all effective compared with the blank control, but all are lower than that of Example 5. Comparative Example 5 (animal-derived collagen) has the worst effect and poses an immunogenicity risk.

[0102] Experimental Example 3 The hemostatic effect of the products in Example 4 and Comparative Examples 1, 3, and 5: Sixty 6-week-old Kunming mice, weighing 25±2 g, were randomly divided into 6 groups, half male and half female, with 10 mice in each group. Each mouse was anesthetized by injecting 3% sodium pentobarbital at a dose of 30 mg / kg. The mice were then fixed and their tails were cut off 1 cm from the end with surgical scissors. Any bleeding was treated immediately with hemostatic materials. The blank group used physiological saline. Groups 4 of Example and Comparative Examples 1, 3, 5, and 6 used the corresponding hemostatic dressings. The positive control group was treated with Yunnan Baiyao powder. Timing was started from the tail cut, and bleeding was considered stopped after 20 minutes. The results are shown in Table 3.

[0103] Table 3. Effects of different products on hemostasis time in mice

[0104] As shown in Table 3, the hemostasis time of Example 4 was the shortest, averaging 128 seconds, significantly better than the positive control group and all comparative groups. Compared with commercially available Yunnan Baiyao, this indicates that the synthesized type I humanized collagen COL1-7 of this invention has excellent procoagulant activity. The hemostasis time of Comparative Example 1 was 158 seconds, faster than the blank control and positive control, but slower than that of Example 4 of this invention. This result indicates that although COL1-Nat retains the core functional domain of type I collagen, its expression stability is extremely poor, and a large number of degradation fragments exist in the fermentation product, resulting in a low proportion of effective components in the actual product, which seriously affects its procoagulant effect. The hemostasis time of Comparative Example 3 was 165 seconds, with poor effect, consistent with its activity data. The hemostasis time of Comparative Example 5 was 175 seconds, with the worst effect, and there was a risk of viral infection.

[0105] Experiment Example 4 This experimental example uses circular dichroism (CD) to detect the synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1: This invention employs circular dichroism (CD) chromatography, a commonly used method in the field, to characterize the structure of collagen. The CD characteristic of the triple helix structure of collagen generally shows a positive absorption peak near 223 nm and a negative absorption peak near 195 nm; the positions of these absorption peaks shift with changes in amino acid sequence and length. A 0.5 mg / mL solution of the synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1 was prepared and subjected to CD detection. The results are as follows... Figure 9 As shown, the maximum characteristic positive peak is at approximately 223 nm, and a negative peak appears at less than 200 nm (198 nm), verifying that the synthesized type I humanized collagen COL1-7 of this invention has a triple helix structure.

[0106] Experimental Example 5 Comparison of anti-degradation properties: The COL1-7 sequences of this invention, along with COL1-Nat (natural continuous sequence repeated 7 times), COL1-Rev (reverse splicing repeated 7 times), COL1-A (repeated 7 times only from positions 425-451), and COL1-B (repeated 7 times only from positions 689-712), were fermented under the same Pichia pastoris expression conditions. The supernatant from 72 h of fermentation was analyzed by SDS-PAGE, and the percentage of the main band was calculated using ImageJ software. The results are shown in Table 4.

[0107] Table 4 Comparison of anti-degradation properties of different recombinant collagens

[0108] As shown in Table 4, the COL1-7 of this invention exhibited an 89% main band ratio and minimal degradation bands during expression in Pichia pastoris, achieving excellent anti-degradation performance while maintaining 100% human sequence integrity. The COL1-Nat main band ratio was only 55%, with multiple obvious degradation bands. This indicates that the natural continuous sequence contains multiple protease recognition sites, which are further amplified after repetition, leading to significant non-specific degradation of the target protein during fermentation, making industrial production difficult. The COL1-Rev main band ratio was 76%, with a small number of degradation bands, and its anti-degradation performance was lower than that of the COL1-7 of this invention, indicating that the fragment splicing order has a significant impact on protein folding efficiency and protease attack site exposure. COL1-A and COL1-B contain only single functional fragments. Although their main band ratios are as high as 96% and 94% respectively, indicating extremely high expression stability, as shown in Table 2 of Example 3, their cell adhesion and proliferation rates are only 62%-65% and 68%-70% respectively, significantly lower than the 100% of the COL1-7 of this invention. This indicates that while retaining only a single functional fragment can improve resistance to degradation, it cannot form a complete biological functional conformation; a single fragment cannot replace the synergistic effect of multiple fragments. The present invention, COL1-7, achieves the optimal balance between resistance to degradation and bioactivity.

[0109] Experimental Example 6 Long-term stability test: The synthetic type I humanized collagen COL1-7 stock solution (5 mg / mL) prepared in Example 1 of this invention was placed at 25℃ and 40℃ for 0, 1, 3 and 6 months, respectively. Samples were taken for SDS-PAGE and UV quantitative detection. The results are shown in Table 5.

[0110] Table 5 Long-term stability of COL1-7

[0111] As shown in Table 5, the synthetic type I humanized collagen COL1-7 stock solution prepared in Example 1 of this invention has good long-term stability at 25℃ and 40℃. After 6 months, the purity is still above 95% and the protein recovery rate is above 94%, making it suitable for industrial production and long-term storage.

[0112] Experimental Example 7 Immunogenicity evaluation: To evaluate the immunogenicity of the synthesized type I humanized collagen COL1-7 of this invention, BALB / c mice were used in the experiment. The synthesized type I humanized collagen COL1-7 stock solution prepared in Example 1 of this invention (experimental group) and Comparative Example 5 (animal-derived type I collagen) were subcutaneously immunized in mice at a dose of 100 μg / mouse, with 10 mice in each group. Immunization was performed on days 0, 14, and 28, respectively. Serum was collected on day 35, and the level of specific IgG antibodies in the serum was detected by ELISA. PBS was used as a blank control group.

[0113] The results are shown in Table 6.

[0114] Table 6 Comparison of serum-specific IgG antibody levels in mice of different groups

[0115] As shown in Table 6, high levels of specific IgG antibodies were produced in the serum of mice in the five control groups, with an antibody titer of 1:2560, indicating that animal-derived collagen has significant immunogenicity. However, the level of specific IgG antibodies in the serum of mice in the group synthesized with type I humanized collagen COL1-7 of this invention was not significantly different from that in the PBS control group (P>0.05), and the antibody titer was less than 1:10. This indicates that the synthesized type I humanized collagen COL1-7 of this invention has extremely low immunogenicity, high safety, and is suitable for use in medical devices and cosmetics.

[0116] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.

Claims

1. A recombinant type I humanized collagen with anti-degradation properties, characterized in that, The recombinant type I humanized collagen includes recombinant collagen single chains; wherein the recombinant collagen single chain is composed of collagen monomer fragments as shown in SEQ ID NO.2 repeated 2-10 times.

2. The recombinant type I humanized collagen according to claim 1, characterized in that, The recombinant collagen single chain is obtained by cutting and splicing human type I collagen α1 chain; wherein the amino acid sequence of the human type I collagen is shown in SEQ ID NO.

1.

3. The recombinant type I humanized collagen according to claim 2, characterized in that, The collagen monomer fragment is obtained by sequentially combining amino acids at positions 425-451 and 689-712 of human type I collagen, wherein the amino acid sequence of human type I collagen is shown in SEQ ID NO.

1.

4. The recombinant type I humanized collagen according to claim 3, characterized in that, The amino acid sequence of the recombinant collagen single chain is shown in SEQ ID NO.

3.

5. The recombinant type I humanized collagen according to claim 3, characterized in that, The nucleotide sequence encoding the recombinant collagen single chain is shown in SEQ ID NO.

4.

6. A method for preparing recombinant collagen single chains, characterized in that, Includes the following steps: Step 1: Design collagen sequences The amino acids at positions 425-451 and 689-712 of human type I collagen are sequentially combined to obtain collagen monomer fragments. The collagen monomer fragments are repeated 2-10 times to obtain recombinant collagen single chains. Step 2, constructing the carrier Based on the recombinant collagen single-chain, the corresponding nucleotide sequence was synthesized to construct a recombinant plasmid; Step 3: Transformation and Cultivation The recombinant plasmid was transferred into host cells, engineered strains were screened, and fermentation culture was performed to induce the expression of the target protein. Step 4: Harvesting and Purification The fermentation broth was collected, the expressed protein product was harvested, and purified to obtain the target collagen.

7. The preparation method according to claim 6, characterized in that, In step two, the plasmid is selected for prokaryotic expression, specifically the pET series vector, pGEX series vector, pBAD series vector, or pUC series vector; or the plasmid is selected for eukaryotic expression, specifically the pcDNA series vector, pCMV series vector, pIRES series vector, pEGFP series vector, pYES series vector, or pPIC series vector.

8. The preparation method according to claim 6, characterized in that, In step three, the host cell is a prokaryotic cell, a yeast cell, or a mammalian cell.

9. The use of an anti-degradation recombinant type I humanized collagen prepared by the method of any one of claims 6-8 in the preparation of collagen-containing products.

10. The application according to claim 9, characterized in that, The collagen products mentioned are cosmetics, medical devices, or pharmaceuticals.

Citation Information

Patent Citations

  • Recombinant human I type collagen and immobilized fermentation production method thereof

    CN105061589A

  • High-stability recombinant collagen as well as construction method and application thereof

    CN116082493A